Monopar Therapeutics MNPR Quick ratio
Quick ratio at other companies
Other financials
Where this comes from
Calculated from Monopar Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's quick ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Monopar Therapeutics's quick ratio?
- Monopar Therapeutics (MNPR) reported quick ratio of 56× in Q1 2026.
- What is the long-term trend for Monopar Therapeutics's quick ratio?
- Over 5 years (2020 to 2025), Monopar Therapeutics's quick ratio has grown at a 29.2% compound annual growth rate (CAGR), from 14.3× to 51.4×.
- What does quick ratio mean?
- Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.